FDA approval

FDA Approves Two Nivolumab-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma Bookmark

The ASCO Post reports on the U.S. Food And Drug Administration (FDA)’s recent approval of two new treatments for advanced, unresectable squamous cell carcinoma of the esophagus.

.

Early Study Finds New Lymphoma Drug Effective Bookmark

According to this Newswise press release from Michigan Medicine – University of Michigan, the U.S. Food and Drug Administration (FDA) has approved the drug zanubrutinib to treat marginal zone lymphoma in some patients, based in part on results from a clinical trial led by researchers at University of Michigan Medical School that demonstrated an 80% response rate.

.

Regularly Updated List of Recent FDA Approvals for Liver Cancer Bookmark

This resource from the U.S. Food and Drug Administration (FDA) lists recent drug approval announcements for liver cancer and related conditions. It also provides link to information about additional approvals that may not be announced.

.

FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma Bookmark

The U.S. Food and Drug Administration (FDA) has approved a cell-based gene therapy known as lisocabtagene maraleucel (brand name Breyanzi) for relapsed or refractory large B-cell lymphoma.

.

Two New Treatments Approved For Advanced Prostate Cancer Bookmark

A story published by the Prostate Cancer Foundation outlines two new treatment options approved by the U.S. Food and Drug Administration (FDA) this year. The two medications, rucaparib and olaparib, each target specific mutations that may be found in a patient’s tumor, and each was approved for a specific type of prostate cancer.

.

First Approval of Second-Line Therapy for DLBCL Bookmark

Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

The FDA has granted accelerated approval to tafasitamab (brand name Monjuvi) as a second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), based upon overall responses seen in a clinical trial. This is the first FDA approval of a second-line treatment for this condition. There are few, if any, other options.

.

Oral Azacitidine Wins FDA Approval for AML Bookmark

Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved oral azacitidine (brand name Onureg) based on clinical trial results showing a 10-month improvement in overall survival for patients with acute myeloid leukemia who are ineligible for transplant.

.

FDA Approves Merck’s Keytruda, Foundation Medicine CDx for TMB-High Solid Tumors Bookmark

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer Bookmark

Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.

Go to full article published by the FDA.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

‘Fail First’ No More: Pennsylvania Moves to Expand Coverage of Treatments for Advanced Cancers Bookmark

Article from The Philadelphia Inquirer curated by Editor in Chief George Lundberg, MD, who notes: 

A new Pennsylvania law requires insurance coverage for use of FDA-approved best drugs first, rather than only after failing with a cheaper alternative.

Go to full article published by The Philadelphia Inquirer.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.